See more : SunMirror AG (ROR1.VI) Income Statement Analysis – Financial Results
Complete financial analysis of Midatech Pharma plc (MTPH.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Midatech Pharma plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Orea Mining Corp. (OREAF) Income Statement Analysis – Financial Results
- Highwealth Construction Corp. (2542.TW) Income Statement Analysis – Financial Results
- Chengdu Xgimi Technology Co.,Ltd. (688696.SS) Income Statement Analysis – Financial Results
- First Midwest Bancorp, Inc. (FMBIO) Income Statement Analysis – Financial Results
- XLMedia PLC (XLM.L) Income Statement Analysis – Financial Results
Midatech Pharma plc (MTPH.L)
About Midatech Pharma plc
Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 699.00K | 578.00K | 343.00K | 674.00K | 1.94M | 7.60M | 6.92M | 1.38M | 157.00K | 147.00K |
| Cost of Revenue | 5.11M | 4.65M | 6.07M | 7.84M | 8.56M | 11.11M | 667.00K | 70.00K | 3.64M | 1.93M |
| Gross Profit | -4.41M | -4.08M | -5.73M | -7.17M | -6.62M | -3.51M | 6.26M | 1.31M | -3.48M | -1.78M |
| Gross Profit Ratio | -631.19% | -705.19% | -1,669.10% | -1,063.65% | -341.43% | -46.24% | 90.37% | 94.91% | -2,217.83% | -1,209.52% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 8.56M | 10.19M | 6.68M | 5.92M | 3.64M | 2.84M |
| General & Administrative | 4.54M | 2.95M | 4.95M | 3.84M | 4.09M | 3.15M | 9.22M | 7.93M | 4.41M | 2.72M |
| Selling & Marketing | 0.00 | 0.00 | 6.00K | 323.00K | 0.00 | 9.42M | 9.52M | 374.00K | 0.00 | 0.00 |
| SG&A | 4.54M | 2.95M | 4.96M | 4.16M | 4.09M | 12.57M | 18.75M | 8.30M | 4.41M | 2.72M |
| Other Expenses | -22.00K | -24.00K | -12.00K | -15.00K | -7.44M | 0.00 | 1.17M | 0.00 | 0.00 | -137.00K |
| Operating Expenses | 4.52M | 2.92M | 4.95M | 4.15M | 5.20M | 12.57M | 25.43M | 14.22M | 4.41M | 2.72M |
| Cost & Expenses | 9.63M | 7.58M | 11.01M | 11.99M | 13.75M | 23.68M | 26.10M | 14.29M | 8.04M | 4.65M |
| Interest Income | 29.00K | 0.00 | 1.00K | 8.00K | 2.00K | 15.00K | 164.00K | 1.69M | 8.00K | 1.00K |
| Interest Expense | 53.00K | 44.00K | 34.00K | 97.00K | 587.00K | 109.00K | 73.00K | 5.00K | 161.00K | 248.00K |
| Depreciation & Amortization | 372.00K | 403.00K | 13.59M | 1.29M | 1.45M | 2.56M | 4.36M | 737.00K | 322.00K | 247.00K |
| EBITDA | -8.56M | -6.60M | -9.45M | -10.03M | -10.36M | -13.56M | -14.65M | -11.23M | -7.56M | -4.39M |
| EBITDA Ratio | -1,224.61% | -1,141.00% | -2,755.98% | -1,487.39% | -534.73% | -178.47% | -211.67% | -816.51% | -4,813.38% | -2,985.03% |
| Operating Income | -8.93M | -7.00M | -23.04M | -11.32M | -11.82M | -17.58M | -30.59M | -12.92M | -7.89M | -4.50M |
| Operating Income Ratio | -1,277.83% | -1,210.73% | -6,717.20% | -1,679.23% | -609.65% | -231.35% | -441.80% | -939.49% | -5,023.57% | -3,060.54% |
| Total Other Income/Expenses | 444.00K | 892.00K | -430.00K | 395.00K | -585.00K | 249.00K | 1.26M | 1.69M | -153.00K | -384.00K |
| Income Before Tax | -8.49M | -6.11M | -23.47M | -10.92M | -12.40M | -17.33M | -29.32M | -11.23M | -8.04M | -4.88M |
| Income Before Tax Ratio | -1,214.31% | -1,056.40% | -6,842.57% | -1,620.62% | -639.83% | -228.07% | -423.54% | -816.87% | -5,121.02% | -3,321.77% |
| Income Tax Expense | -832.00K | -646.00K | -1.28M | -1.79M | -2.03M | -1.27M | -9.16M | -1.13M | -658.00K | -799.00K |
| Net Income | -7.66M | -5.46M | -22.19M | -9.14M | -10.37M | -16.06M | -20.16M | -10.10M | -7.38M | -4.08M |
| Net Income Ratio | -1,095.28% | -944.64% | -6,469.10% | -1,355.79% | -534.98% | -211.42% | -291.23% | -734.47% | -4,701.91% | -2,778.23% |
| EPS | 0.00 | -1.36 | -10.36 | -9.06 | -66.85 | -123.37 | -220.28 | -141.88 | -322.33 | -57.91 |
| EPS Diluted | 0.00 | -1.36 | -10.36 | -9.06 | -66.85 | -123.37 | -220.28 | -141.88 | -322.33 | -57.91 |
| Weighted Avg Shares Out | 0.00 | 4.03M | 2.14M | 1.01M | 155.10K | 130.21K | 91.53K | 71.18K | 22.90K | 70.52K |
| Weighted Avg Shares Out (Dil) | 0.00 | 4.03M | 2.14M | 1.01M | 155.10K | 130.21K | 91.53K | 71.18K | 22.90K | 70.52K |
Source: https://incomestatements.info
Category: Stock Reports